Your English writing platform
Discover LudwigExact(2)
The patient described here had favorable long-term survival after diagnosis of liver metastasis, which may demonstrate that a select group of patients with isolated liver metastasis can benefit from aggressive systemic HER2-directed chemotherapy and complete surgical resection, even without continuous chemotherapy.
The classification of breast cancer patients into risk groups provides a powerful tool for the identification of patients who will benefit from aggressive systemic therapy.
Similar(58)
We hypothesized that intravascular skin-limited ALCL is distinct from aggressive systemic intravascular lymphomas in its intralymphatic localization and clinical course.
Molecular approaches may hence provide a reliable means of identifying patients who may benefit from more aggressive systemic treatment, i.e. whose tumors are clonally related and more likely to be associated with metastatic disease.
Patients with hepatic and pulmonary metastases from colorectal cancer (CRC) may benefit from aggressive surgical therapy.
Patients with a prior DVT are unlikely to benefit from aggressive arterial or venous reconstruction.
Further studies are needed to identify a subgroup of patients who may benefit from aggressive multidisciplinary treatment including liver metastasectomy.
Most of chemotherapeutic agents show significant side effects and not all patients benefit from aggressive chemotherapy.
However, some subsets of patients may benefit from aggressive treatment.
Thus, this population may benefit from aggressive Medicaid enrollment.
Our findings indicated that patients can benefit from aggressive radiation treatment (≥63 Gy) to the primary tumor based on the delivery of a sufficient number of cycles (≥4 cycles) of systemic chemotherapy.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com